Reagents for HCV antigen-antibody combination assays

Patent metadata

Field	Value
Publication number	US-9915658-B2
Application number	US-201514982015-A
Country	US
Kind code	B2
Filing date	Dec 29, 2015
Priority date	May 20, 2009
Publication date	Mar 13, 2018
Grant date	Mar 13, 2018

Abstract

The present invention is directed to combination immunoassays, reagents and kits for simultaneous detection of HCV antigens and anti-HCV antibodies in a sample. The combination immunoassays of the present invention employ a non-ionic detergent that effectively exposes or releases the HCV core antigen from virions in a sample without interfering with the performance of other reagents such as the capture of anti-HCV antibodies by recombinant HCV antigens.

First claim

What is claimed is:

1. An immunoassay for simultaneously detecting HCV antigens and antibodies in a sample, comprising:
providing a non-ionic detergent Lauryldimethylamine N-oxide (LDAO), a first pair of a capture antigen and a detection antigen, a first pair of a capture antibody and a conjugate antibody, wherein said capture antigen and said detection antigen both comprise a first peptide fragment of a first HCV protein, said capture antibody and said conjugate antibody specifically bind to a second HCV protein, and said detection antigen and said conjugate antibody comprise one and same signal generating means;
contacting said sample in the presence of said detergent with said capture antigen, said detection antigen, said capture antibody and said conjugate antibody, to form a sandwich complex between said capture antigen, said detection antigen, and an anti-HCV antibody present in said sample, and a complex between said capture antibody, said conjugate antibody, and an HCV antigen present in said sample; and
measuring a signal generated from said signal-generating means as a result of the formation of said complexes, thereby simultaneously detecting HCV antigens and antibodies in said sample.

2. The immunoassay of claim 1 , wherein said first HCV protein and second HCV protein are independently selected from the group consisting of the core antigen, E1, E2, NS2, NS3, NS4, and NS5.

3. The immunoassay of claim 1 , wherein said first HCV protein and said second HCV protein are the same, and said capture antibody and said conjugate antibody bind to a region of said second HCV protein outside of said first peptide fragment.

4. The immunoassay of claim 3 , wherein said first HCV protein and said second HCV protein are both the HCV core antigen.

5. The immunoassay of claim 1 , wherein a second pair of a capture antigen and a detection antigen is provided, wherein said capture antigen and said detection antigen of the second pair both comprise a second peptide fragment of an HCV protein, wherein said second peptide fragment is different from said first peptide fragment.

6. The immunoassay of claim 1 , wherein said capture antibody in said first pair comprises two or more antibodies.

7. The immunoassay of claim 1 , wherein a second pair of a capture antibody and a conjugate antibody is provided, wherein said capture antibody and said conjugate antibody in said second pair specifically bind to said second HCV protein or a different HCV protein.

8. The immunoassay of claim 1 , wherein said capture antigen and said capture antibody are attached to a solid phase.

9. The method of claim 1 , wherein LDAO is present in the range of 0.1 to 2.0%.

10. The method of claim 9 , wherein LDAO is present in the range of 0.3 to 1.0%.

Assignees

• Ortho Clinical Diagnostics Inc

Inventors

• Zheng Jian
• Yang Jianping

Classifications

• G01N33/5306

  Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding · CPC title

• G01N2469/10

  Detection of antigens from microorganism in sample from host · CPC title

• G01N2333/186

  Hepatitis C; Hepatitis NANB · CPC title

• G01N33/5767 Primary

  non-A, non-B hepatitis · CPC title

• G01N33/56983 Primary

  Viruses · CPC title